UPDATE: Goldman Sachs Downgrades Seres Therapeutics (MCRB) to Sell

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to UPDATE: Goldman Sachs Downgrades Seres Therapeutics (MCRB) to Sell

Seres Therapeutics (MCRB) PT Lowered to $18 at Oppenheimer, Following CLinical Business Update

July 22, 2021 4:17 PM EDT

Oppenheimer analyst Mark Breidenbach lowered the price target on Seres Therapeutics (NASDAQ: MCRB) to $18.00 (from $36.00) while maintaining a Outperform rating.

... More

Seres Therapeutics (MCRB) PT Lowered to $21 at Jefferies, Following Clinical Business Update

July 22, 2021 2:18 PM EDT

Jefferies analyst Brian Mills lowered the price target on Seres Therapeutics (NASDAQ: MCRB) to $21.00 (from $41.00) while maintaining a Buy rating.

... More

Seres Therapeutics (MCRB) PT Lowered to $32 at Piper Sandler, Following Clinical Business Update

July 22, 2021 12:42 PM EDT

Piper Sandler analyst Edward A. Tenthoff lowered the price target on Seres Therapeutics (NASDAQ: MCRB) to $32.00 (from $40.00) while maintaining a Overweight rating.

... More

Seres Therapeutics (MCRB) SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis Did Not Meet its Primary Endpoint

July 22, 2021 7:04 AM EDT

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC). The study did not meet its primary endpoint of improving clinical remission rates compared... More